{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:28:03Z","timestamp":1777526883193,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"crossref","award":["2013CB531805"],"award-info":[{"award-number":["2013CB531805"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"NSF of China","doi-asserted-by":"crossref","award":["81473181"],"award-info":[{"award-number":["81473181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"NSF of China","doi-asserted-by":"crossref","award":["81273590"],"award-info":[{"award-number":["81273590"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"NSF of China","doi-asserted-by":"crossref","award":["81403003"],"award-info":[{"award-number":["81403003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"NSF of China","doi-asserted-by":"crossref","award":["81302793"],"award-info":[{"award-number":["81302793"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"State Key Laboratory of Organ Failure Research, Southern Medical University","award":["KF1501"],"award-info":[{"award-number":["KF1501"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.taap.2016.04.009","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T19:59:30Z","timestamp":1460836770000},"page":"42-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases"],"prefix":"10.1016","volume":"301","author":[{"given":"Xia","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Ze","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Feng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Bo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2016.04.009_bb0005","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/00498254.2013.840750","article-title":"Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases","volume":"44","author":"Ai","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1016\/j.taap.2016.04.009_bb0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/03602530903209288","article-title":"Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system","volume":"42","author":"Court","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.taap.2016.04.009_bb0015","doi-asserted-by":"crossref","first-page":"1-&","DOI":"10.1016\/0006-2944(71)90069-X","article-title":"Mechanism of bilirubin toxicity on tissue culture cells - factors that affect toxicity, reversibility by albumin, and comparison with other respiratory poisons and surfactants","volume":"5","author":"Cowger","year":"1971","journal-title":"Biochem. Med."},{"key":"10.1016\/j.taap.2016.04.009_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s002280050068","article-title":"Multiple dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects","volume":"50","author":"Dingemanse","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2016.04.009_bb0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.taap.2012.12.019","article-title":"Structure-inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs)","volume":"267","author":"Fang","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2016.04.009_bb0030","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1194\/jlr.M040519","article-title":"A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids predicts possible metabolic disorders","volume":"54","author":"Fang","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.taap.2016.04.009_bb0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00280-010-1445-3","article-title":"The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1","volume":"67","author":"Fujita","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2016.04.009_bb0040","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/mol.62.3.608","article-title":"Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)","volume":"62","author":"Gagne","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.taap.2016.04.009_bb0045","doi-asserted-by":"crossref","first-page":"42108","DOI":"10.1074\/jbc.M106742200","article-title":"Homodimerization of human bilirubin-uridine-diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) and its functional implications","volume":"276","author":"Ghosh","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2016.04.009_bb0050","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2014.126","article-title":"Pharmacogenomics of human uridine Diphospho-glucuronosyltransferases and clinical implications","volume":"96","author":"Guillemette","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.04.009_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-2999(02)02383-X","article-title":"Effects of entacapone and tolcapone on mitochondrial membrane potential","volume":"453","author":"Haasio","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2016.04.009_bb0060","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.chemosphere.2013.06.070","article-title":"New insights for the risk of bisphenol A: inhibition of UDP-glucuronosyltransferases (UGTs)","volume":"93","author":"Jiang","year":"2013","journal-title":"Chemosphere"},{"key":"10.1016\/j.taap.2016.04.009_bb0065","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0009-9236(98)90088-1","article-title":"Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites","volume":"63","author":"Jorga","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.04.009_bb0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","article-title":"UDP-glucuronosyltransferases and clinical drug-drug interactions","volume":"106","author":"Kiang","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.04.009_bb0075","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1124\/dmd.110.034736","article-title":"Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution","volume":"38","author":"Kirby","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0080","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0090-9556(24)15088-X","article-title":"The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases","volume":"28","author":"Lautala","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0085","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1124\/dmd.109.030734","article-title":"Identification and characterization of human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of daphnetin","volume":"38","author":"Liang","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pharmthera.2008.01.006","article-title":"In vitro measurements of metabolism for application in pharmacokinetic modeling","volume":"118","author":"Lipscomb","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.taap.2016.04.009_bb0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.109.029660","article-title":"Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases","volume":"38","author":"Liu","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2015.05.003","article-title":"An optimized ratiometric fluorescent probe for sensing human UDP-glucuronosyltransferase 1A1 and its biological applications","author":"Lv","year":"2015","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.taap.2016.04.009_bb0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpba.2014.01.025","article-title":"Simultaneous determination of bilirubin and its glucuronides in liver microsomes and recombinant UGT1A1 enzyme incubation systems by HPLC method and its application to bilirubin glucuronidation studies","volume":"92","author":"Ma","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.taap.2016.04.009_bb0110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.taap.2014.02.021","article-title":"Herb\u2013drug interaction prediction based on the high specific inhibition of andrographolide derivatives towards UDP-glucuronosyltransferase (UGT) 2B7","volume":"277","author":"Ma","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2016.04.009_bb0115","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/tx049898m","article-title":"Human UDP-glucuronosyltransferase 1A1 is the primary enzyme responsible for the N-glucuronidation of N-hydroxy-PhIP in vitro","volume":"17","author":"Malfatti","year":"2004","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.taap.2016.04.009_bb0120","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1212\/01.wnl.0000187066.81162.70","article-title":"Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism","volume":"65","author":"Martignoni","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.taap.2016.04.009_bb0125","doi-asserted-by":"crossref","first-page":"6403-&","DOI":"10.1016\/S0021-9258(18)63479-9","article-title":"Effects of bilirubin on mitochondrial reactions","volume":"244","author":"Mustafa","year":"1969","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2016.04.009_bb0130","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/sj.onc.1209375","article-title":"Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer","volume":"25","author":"Nagar","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.taap.2016.04.009_bb0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/archneur.57.2.263","article-title":"Tolcapone and hepatotoxic effects","volume":"57","author":"Olanow","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.taap.2016.04.009_bb0140","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1124\/dmd.30.12.1364","article-title":"Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1","volume":"30","author":"Rios","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s002280050657","article-title":"Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition","volume":"55","author":"Rouru","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2016.04.009_bb0150","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1124\/dmd.113.056291","article-title":"Optimized methods for targeted peptide-based quantification of human uridine 5 \u2018-diphosphate-glucuronosyltransferases in biological specimens using liquid chromatography-tandem mass spectrometry","volume":"42","author":"Sato","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0155","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1474-4422(05)70098-3","article-title":"Entacapone in the treatment of Parkinson's disease","volume":"4","author":"Schrag","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.taap.2016.04.009_bb0160","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.pediatrneurol.2003.09.011","article-title":"Bilirubin toxicity in the developing nervous system","volume":"29","author":"Shapiro","year":"2003","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.taap.2016.04.009_bb0165","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia","volume":"21","author":"Singer","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2016.04.009_bb0170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1021\/tx025569n","article-title":"In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity","volume":"16","author":"Smith","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.taap.2016.04.009_bb0175","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.3748\/wjg.v19.i38.6398","article-title":"New insights in bilirubin metabolism and their clinical implications","volume":"19","author":"Sticova","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.taap.2016.04.009_bb0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/CIA.S3787","article-title":"Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease","volume":"4","author":"Truong","year":"2009","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.taap.2016.04.009_bb0185","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/dmd.105.007369","article-title":"Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) \u201cprobes\u201d for human UDP-glucuronosyltransferases","volume":"34","author":"Uchaipichat","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0190","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0195","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2016.04.009_bb0200","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.taap.2015.09.003","article-title":"Identification and characterization of naturally occurring inhibitors against UDP-glucuronosyltransferase 1A1 in Fructus Psoraleae (Bu-gu-zhi)","volume":"289","author":"Wang","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2016.04.009_bb0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/dmd.32.3.281","article-title":"Glucuronidation and the UDP-glucuronosyltransferases in health and disease","volume":"32","author":"Wells","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0090-9556(25)07341-6","article-title":"Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans","volume":"21","author":"Wikberg","year":"1993","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0215","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","article-title":"Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios","volume":"32","author":"Williams","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0220","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2133\/dmpk.DMPK-13-RG-059","article-title":"Identification and characterization of human UDP-glucuronosyltransferases responsible for the glucuronidation of fraxetin","volume":"29","author":"Xia","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.taap.2016.04.009_bb0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.fct.2016.02.007","article-title":"Assessment of the inhibition potential of Licochalcone A against human UDP-glucuronosyltransferases","volume":"90","author":"Xin","year":"2016","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.taap.2016.04.009_bb0230","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","article-title":"Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism","volume":"102","author":"Xu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.taap.2016.04.009_bb0235","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1021\/js970236+","article-title":"Effect of valproate on the pharmacokinetics of free and total plasma bilirubin in experimental hyperbilirubinemia in guinea pigs","volume":"87","author":"Yu","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.taap.2016.04.009_bb0240","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1124\/dmd.113.055962","article-title":"Hepatic glucuronidation of isoneochamaejasmin a from the traditional Chinese medicine Stellera chamaejasme L. Root","volume":"42","author":"Yu","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0245","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0250","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.04.009_bb0255","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3109\/00498254.2012.681814","article-title":"Potent and selective inhibition of magnolol on catalytic activities of UGT1A7 and 1A9","volume":"42","author":"Zhu","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.taap.2016.04.009_bb0260","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.taap.2015.01.003","article-title":"Diethylstilbestrol can effectively accelerate estradiol-17-O-glucuronidation, while potently inhibiting estradiol-3-O-glucuronidation","volume":"283","author":"Zhu","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2016.04.009_bb0265","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1073\/pnas.231140698","article-title":"Mechanism of indinavir-induced hyperbilirubinemia","volume":"98","author":"Zucker","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X16300849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X16300849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:44:01Z","timestamp":1748893441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X16300849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":53,"alternative-id":["S0041008X16300849"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2016.04.009","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2016.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}